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Treatment with the somatostatin receptor (sst) subtype 2 pre-
dominant analogs octreotide and lanreotide induces clinical
and biochemical cure in approximately 65% of acromegalic
patients. GH-secreting pituitary adenomas, which are not
controlled, also express sst5. We compared the acute effects of
octreotide and SOM230, a new somatostatin analog with high
affinity for sst1,2,3,5 on hormone release in acromegalic pa-
tients. In a single-dose, proof-of-concept study, 100 g oct-
reotide and 100 and 250 g SOM230 were given sc to 12 pa-
tients with active acromegaly. Doses of 100 and 250g SOM230
dose-dependently suppressed GH levels from 2–8 h after ad-
ministration (38  7.7 vs. 61  6.7%, respectively; P < 0.01).
A comparable suppression of GH levels by octreotide and 250
g SOM230 was observed in eight patients (65  7 vs. 72 
7%, respectively). In three patients, the acute GH-lowering
effect of 250 g SOM230 was significantly superior to that of
octreotide (70  2 vs. 17  15%, respectively; P < 0.01). In
one patient, the GH-lowering effect of octreotide was better
than that of SOM230. Tolerability for SOM230 was good. Glu-
cose levels were initially slightly elevated after octreotide and
SOM230, compared with control day, whereas insulin levels
were only significantly suppressed by octreotide. We conclude
that SOM230 is an effective GH-lowering drug in acromegalic
patients with the potential to increase the number of patients
controlled during long-term medical treatment. (J Clin En-
docrinol Metab 89: 638–645, 2004)
IN THE MAJORITY of patients, acromegaly is caused by aGH-secreting pituitary adenoma, resulting in high cir-
culating GH and IGF-I concentrations. The first choice of
medical treatment are the somatostatin (SS) analogs, a safe
and effective strategy, mimicking the action of the native
peptide SS in its inhibitory effect on GH release by the ad-
enoma cells (1). The first clinically available SS analog oct-
reotide (OCT) has been shown to be effective as primary or
secondary therapy for acromegalic patients (2–5). Several
studies have demonstrated that long-term therapy with OCT
or lanreotide, administered either sc or as a long-acting depot
preparation by im injection, induced clinical and biochemical
cure in approximately 65% of patients (6–10). Still, a signif-
icant percentage of GH-secreting pituitary tumors seems rel-
atively resistant to OCT and lanreotide, and this may be
explained in part by a variable tumoral expression or re-
duced receptor density of the five known SS receptor (sst)
subtypes on the adenomas of these patients (11). Functional
evidence for the existence of sst subtypes comes from studies
using human fetal pituitary cell cultures in which SS regu-
lates GH and TSH secretion mainly by sst2 and sst5 and
prolactin (PRL) secretion mainly by sst5 (12). Most GH-
secreting pituitary adenomas predominantly express mRNA
for sst2 and sst5, whereas sst1 and sst3 are moderately ex-
pressed and sst4 not found (13, 14). SS binds with high af-
finity to all five sst subtypes, whereas OCT and lanreotide
display a high, low, and moderate affinity to sst2, sst14, and
sst35, respectively. Saveanu et al. (15) compared the in vivo
sensitivity of GH release for OCT in nine acromegalic pa-
tients with the tumor mRNA expression for sst2 and sst5
subtypes. It was observed that sst2 mRNA expression was
lower, and sst5 mRNA was higher in adenomas that were
partially sensitive to OCT, compared with OCT-sensitive
adenomas. In the group of partially OCT-sensitive tumors,
both the sst5-preferential analog BIM23268 and especially the
sst2 and sst5 bispecific compound BIM23244, were quite ef-
fective in suppressing GH secretion. These data indicate that
due to the heterogeneous expression of sst2 and sst5 subtypes
in GH-secreting adenomas, a bispecific analog, such as BIM-
23244 that can activate both receptors, may achieve a better
control of GH hypersecretion of GH-producing pituitary tu-
mors than OCT.
Bruns et al. (16) and Lewis et al. (17) synthesized SOM230,
a stable SS analog with a more universal binding profile to
sst subtypes. By using alanine scanning technology, essential
functional groups of the SS peptide responsible for the high
affinity to all five sst subtypes were detected. Incorporation
of four synthetic amino acids and two essential amino acids
of SS into a stable cyclohexapeptide template resulted in
SOM230, a compound that binds with a high affinity to sst1,
sst2, sst3, and sst5 and with low affinity to sst4. In rats, dogs,
Abbreviations: CD, Control day; HPRT, hypoxanthine-guanine phos-
phoribosyl transferase; OCT, octreotide; oGTT, oral glucose tolerance
test; PRL, prolactin; SS, somatostatin; sst, SS receptor.
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and monkeys, SOM230 potently and dose-dependently de-
creases GH and IGF-I levels. Only minimal desensitization of
the suppressing effect of SOM230 on IGF-I levels under phys-
iological conditions was observed, which is in contrast to
what has been seen in rodents with the effect of OCT. Ad-
ditional characteristics of SOM230 include a favorable ter-
minal elimination half-life of 27 h in humans as well as the
preliminary evidence that glucose levels in rats and dogs
remain normal during long-term administration of the
compound.
Here, we present the detailed analysis of the first single-
dose, proof-of-concept study with SOM230 in acromegalic
patients. A double-blind, randomized, crossover study was
performed to compare the in vivo effects of a single dose of
SOM230 to OCT on GH release, to assess its safety and
tolerability in 12 patients with active acromegaly.
Patients and Methods
Patients
Twelve patients with active acromegaly were recruited at the Eras-
mus Medical Center in Rotterdam, The Netherlands. All subjects had
biochemically active disease, with a mean serum GH concentration
greater than 5g/liter during a 5-h profile and elevated circulating IGF-I
levels (age and sex adjusted). GH concentration failed to suppress less
than 1 g/liter after a 2-h 75-g oral glucose tolerance test (oGTT). Table
1 shows the biochemical characteristics of the 12 patients. One insulin-
treated patient with type 2 diabetes did not undergo an oGTT. Seven
patients had been treated before (see below). In those patients who have
been medically treated previously, a washout period after the last dose
of medication had to be at least 1 month, 1 wk, 4 months, and 1 month
for dopamine agonists, sc formulations of OCT, depot formulations of
long-acting somatostatin analogs, and GH receptor antagonists, respec-
tively. One patient had been previously treated by surgery, medical
treatment, and irradiation. One patient was treated only with surgery.
Two patients had only been medically treated, and three patients were
treated with surgery and medical treatment. Five patients were newly
diagnosed. Patients with compression of the optic chiasm causing any
visual field defect or those requiring surgical intervention for relief of
any sign or symptom possibly associated with tumor compression were
excluded. The study was approved by the local ethical committee of the
Erasmus Medical Center, and all patients gave written informed consent.
Treatment protocol
Patients were hospitalized on the control day (CD) for 24 h for the
assessment of baseline efficacy parameters. On study d 1, 8, and 15, each
patient received at 0900 h a single sc injection of 100 g OCT, 100 g
SOM230, or 250g SOM230 in a randomized, double-blinded, crossover
fashion with a minimum 6 d of washout between drug treatments. All
patients received standarized meals, served at 0830, 1230, and 1730 h.
Blood samples, withdrawn through an indwelling venous catheter
placed in the forearm, for the assessment of GH and PRL concentrations,
were collected at 30 min, 1 min before, and every hour for 24 h after drug
administration. This procedure was repeated on all study days. Fur-
thermore, blood samples for glucose and insulin assessments were col-
lected 30 min, 1 min before, and every half-hour for 2 h after lunch. Blood
specimens were centrifuged, and the plasma was frozen at 20 C until
it was assayed.
Safety assessments included vital signs (pulse rate, blood pressure,
and temperature); electrocardiograms; biochemistry; hematology; and
urinalysis.
Assays
GH (micrograms/liter), PRL (micrograms/liter), and insulin (milli-
units/liter; 1 mU/liter  7.175 pmol/liter) levels were determined by
use of a nonisotopic, automatic chemiluminescence immunoassay sys-
tem [Immulite; Diagnostic Products Corp., Los Angeles, CA]. The intra-
and interassay coefficients of variation for GH, PRL, and insulin were
6.0, 5.7, 4.4, and 6.2, 6.4, 5.9%, respectively. Glucose (millimoles/liter; 1
mmol/liter  18.015 mg/dl) was measured with an automatic hexoki-
nase method (Roche, Almere, The Netherlands). Serum IGF-I (micro-
grams/liter) was determined with a commercially available nonextrac-
tion immunoradiometric assay (Diagnostic Systems Laboratories, Inc.,
Webster, TX) (intra- and interassay coefficients of variation, 3.9 and 4.2%,
respectively).
In vitro studies
Two patients underwent transphenoidal surgery 3 months before
they entered the study. Adenomatous tissue was collected during op-
eration, and, subsequently, pituitary adenoma cells were isolated as
described previously (18). The viability of the resulting cell suspension,
as determined by trypan blue dye exclusion, was greater than 95%. The
cells were cultured at a density of 0.5–1 105 cells/dish1 ml in multiwell
plates (Corning Costar, Cambridge, MA). The culture medium was
Eagle’s MEM with Earle’s salts supplemented with a 1-fold excess of
nonessential amino acids, 1 mm sodium pyruvate, 2 mm l-glutamine,
100 U/ml penicillin, 100 g/ml streptomycin, and 0.25 g/ml fungi-
zone, and 10% fetal calf serum (Invitrogen, Breda, The Netherlands).
Media and supplements were obtained from Life Technologies, Inc.
Bio-Cult Europe (Invitrogen). The cells were allowed to attach for at least
3 d before a 72-h incubation with SS (Sigma, St. Louis, MO), OCT, or
SOM230 (both donated by Novartis, Basel, Switzerland) in 1 ml complete
culture medium performed with the attached cells, using four dishes for
every treatment group. These pituitary cell cultures are primary cultures
that were plated immediately after the isolation, and they were not
TABLE 1. Patients characteristics on study entry
Patient Sex Age (yr) GH (g/liter)a PRL (g/liter)a IGF-I(g/liter)b
GH after oGTT
(g/liter)c
1 F 43 13.6 13.8 1981 10.1
2 M 34 7.4 18.1 1301 8.3
3 F 55 31.6 3.4 1385 29.1
4 M 48 26.5 7.8 1515 ND
5 F 36 31.1 7.2 941 21.2
6 M 35 48.1 19.1 1729 29.0
7 M 38 19.5 20.9 2027 16.9
8 M 33 11.0 10.3 1920 11.0
9 F 79 19.3 0.7 1148 24.6
10 M 67 6.9 17.7 849 5.5
11 F 52 5.8 9.8 773 2.5
12 F 40 57.4 6.7 2180 75.0
F, Female; M, male; ND, not determined.
a Mean fasting GH and PRL values, collected in a 5-h time period. Normal values: GH, 5 g/liter; PRL, 25 g/liter (men) or 44 g/liter
(women).
b Range in healthy population: 107–497 g/liter.
c Serum GH level after a 2-h 75-g OGTT (normal nadir GH, 1 g/liter after 2 h).
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passaged before the incubation studies were performed. The results of
each experiment were expressed as nanograms per dish and compared
with control untreated dishes.
Quantitative RT-PCR
Quantitative RT-PCR was performed as described previously (19).
Briefly, poly A mRNA was isolated during Dynabeads Oligo (dT)25
(Dynal AS, Oslo, Norway) from adenoma cell pellets containing 0.5–1
106 cells/sample. cDNA was synthesized using the poly A mRNA
captured on the Dynabeads Oligo (dT)25 as a solid-phase and first
primer. To quantify sst2 and sst5 mRNAs, a quantitative RT-PCR was
performed by TaqMan Gold nuclease assay (Perkin-Elmer Corp., Foster
City, CA) and the ABI PRISM 7700 sequence detection system (Perkin-
Elmer Corp.) for real-time amplification, according to the manufactur-
er’s instructions. The specific primer sequences (Biosource, Nivelles,
Belgium) that were used include: sst2 forward, 5-TCGGCCAAGTG-
GAGGAGAC-3; sst2 reverse, 5-AGAGACTCCCCACACAGCCA-3;
sst5 forward, 5-CATCCTCTCCTACGCCAACAG-3; sst5 reverse, 5-
GGAAGCTCTGGCGGAAGTT-3; hypoxanthine-guanine phosphori-
bosyl transferase (HPRT; as a control) forward, 5-TGCTTTCCTTGGT-
CAGGCAGTAT-3; HPRT reverse, 5-TCAAATCCAACAAAGTCTG-




of sst2 and sst5 mRNA was determined by means of a standard curve
generated in each experiment from known amounts of human genomic
DNA. For the determination of the amount of HPRT mRNA, a standard
curve was obtained by including dilutions of a pool cDNA known to
contain HPRT. The amount of sst2 and sst5 mRNA was calculated rel-
ative to the amount of HPRT and is given in arbitrary units.
Statistical analysis
The assumption of normality of all in vivo data was investigated by
use of a Kolmogorov-Smirnov test, in which the null hypothesis that the
data represented a random sample from the normal distribution was
tested. When this hypothesis was not rejected, a paired Student’s t test
was used for assessing the statistical significance, compared with the
CD. The Wilcoxon’s signed rank test, a nonparametric analog to the
paired t test, was used when data did not represent a random sample
from normal distribution. Correlation analysis was performed by the use
of Spearman’s rank correlation test. In the in vitro studies, one-way
ANOVA was used. When significant overall effects were obtained by
this method, comparisons were made using Newman-Keuls multiple




Tolerability of OCT and SOM230 was good. Local reac-
tions at the injection site were not observed. Side effects
probably related to the study drug were reported in three
different patients and were mild (one case of palpitation and
sweating after 100 g SOM230, one case of abdominal dis-
comfort after 100 g OCT and after 250 g SOM230). No
clinically relevant changes in vital signs, routine chemistry,
and urinalysis were observed. Electrocardiogram analyses
showed no newly occurring or worsening of known cardiac
abnormalities 2 and 24 h after injection with OCT or SOM230.
In vivo studies
Figure 1 depicts the mean circulating 24-h GH concentra-
tions after a single sc injection of 100 g OCT, 100 g
SOM230, and 250 g SOM230, compared with CD, for all
acromegalic patients investigated. Because all three treat-
ment options appeared to induce their effect on GH secretion
predominantly immediately after sc injection, efficacy anal-
ysis of OCT and the two dosages of SOM230 was assessed by
analysis of the mean GH suppression between 2 and 8 h after
sc injection, compared with the same period on the CD. The
mean GH levels from 2–8 h after 250 g SOM230, 100 g
SOM230, and OCT were suppressed by 61  6.7% (P 
0.0001), 38  7.7% (P  0.001), and 59  9.2% (P  0.0001),
respectively. Furthermore, the 250-g dosage of SOM230
induced a significantly greater suppressive effect on circu-
lating GH concentrations than the 100-g dosage of SOM230
(P 0.01). The inhibitory effect of OCT on GH levels did not
differ from SOM230 250 g (P  not significant), whereas,
compared with 100 g SOM230, a stronger suppression of
GH concentrations by OCT was found, although this differ-
ence failed to reach statistical significance (P  0.13).
Analysis of the 12 individual 24-h GH profiles on CD and
after administration of the study drugs, revealed three dif-
ferent patterns of response. As illustrated by the 24-h GH
profile of patient 6 (Fig. 2A), both OCT and 250 g SOM230
induced a similar inhibitory effect on circulating GH con-
centrations [63%, plasma GH levels 18.9 1.1g/liter after
OCT (P  0.05) and 65%, plasma GH levels 17.7  1.7
g/liter after SOM230 (P 0.01), both vs. 50.8 4.5 g/liter
on CD]. A comparable suppressive effect on GH levels by 250
g OCT and SOM230 was observed in a total of eight pa-
tients. In this subgroup of eight equal responders, both
SOM230 and OCT significantly suppressed GH levels by
65  7% (8.0  2.7 vs. 20.4  6.5 g/liter on CD, P  0.05)
and 72 7% (7.5 3 vs. 20.4 6.5 g/liter on CD, P 0.05;
OCT vs. SOM230, P not significant), respectively (Fig. 3A).
The second pattern of response to the study drugs, ob-
served in a subgroup of three patients, is illustrated by the
24-h GH profile of patient 12 (Fig. 2B). In this particular
patient, no decline in circulating GH concentrations after
OCT administration was seen (mean plasma GH level 76.7
7.3 vs. 67.4  4.8 g/liter on CD). However, a significant
suppression of serum GH levels after administration of
SOM230 was found (68%; 21.9 2.2 g/liter vs. 67.4 4.8
FIG. 1. Twenty-four-hour GH concentration curves on the CD (f—f)
and treatment days after sc injection of 100 g OCT (*—*),250 g
SOM230 (Œ—Œ), and 100 g SOM230 (E—E). Data are expressed as
mean  SEM (n  12).
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g/liter on CD, P  0.05; SOM230 vs. OCT, P  0.01), and,
interestingly, in this particular patient the observed potent
suppression by the high-dose 250 g SOM230 was also
achieved by the low-dose 100 g SOM230 (64%; 24.4 3.4
g/liter). As shown in Fig. 3B, the mean suppression of GH
levels in these three patients by SOM230 was significantly
greater than the suppressive effect by OCT [70 2%, 9.7
6 g/liter and 17  15%, 30.9  23 g/liter, respectively,
vs. 30.5  19 g/liter on CD (SOM230 vs. CD, P  0.01;
SOM230 vs. OCT, P  0.05 and OCT vs. CD, P  n.s.)].
Patient 8 demonstrated a third observed response pattern
(Fig. 2C), which showed a significant inhibition by OCT
(79%; mean GH level, 2.9  0.7 vs. 13.8  0.6 g/liter on
CD; P  0.01). SOM230 was not effective during the full 2-
to 8-h postinjection time interval to elicit an inhibitory effect
on circulating GH concentrations (14.5  1.9 vs. 13.8  0.6
g/liter on CD, P  not significant). However, this patient
was not insensitive to SOM230 because a short-lasting sup-
pressive effect of SOM230 was established (40%; mean GH
level 1–3 h after administration, 7.2  0.4 vs. 12.4  0.2
g/liter on CD; P  0.001). Still, in this short period of time,
OCT induced a more powerful 87% suppression of GH con-
FIG. 2. Twenty-four-hour GH concentration curves of the different
response patterns after sc injection of the study drugs, represented by
patients 6 (A), 12 (B), and 8 (C). Symbols display CD (f—f), 100 g
OCT (*—*), and 250 g SOM230 (Œ—Œ).
FIG. 3. GH suppression 2–8 h after sc injection. The bars represent
mean SEM percentual GH suppression induced by 100 g octreotide
(f) and 250g SOM230 (), compared with the CD. A, Group showing
equal response to OCT and SOM230 (n 8). B, Group showing higher
sensitivity to SOM230 (n  3; *, P  0.05).
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centrations (1.6  0.3 g/liter; OCT vs. CD, P  0.001; OCT
vs. SOM230, P  0.001).
PRL levels of all 12 patients were within the normal range
[mean of five blood samples, 25 g/liter (men) or 44 g/
liter (women); Table 1]. In two patients, plasma PRL levels
decreased after sc injection of OCT as well as with SOM230
(data not shown). Interestingly, the 24-h circulating plasma
curves of GH and PRL levels in one of these patients was
highly correlated on CD and at treatment days with OCT and
SOM230 (rs 0.77, 0.99, and 0.95, respectively, all P 0.001),
which suggests a mixed GH/PRL-secreting pituitary ade-
noma that cosecreted both hormones from the same ade-
noma cell.
Figure 4 shows the mean glucose and insulin concentra-
tions of 11 patients (patient 4 was excluded because he was
an insulin-treated patient with type 2 diabetes), starting 3 h
after sc administration until 2 h after lunch, compared with
the same period of time on CD. Compared with the mean
glucose level at 1200 h (3 h after dose) on CD (4.4  0.2
mmol/liter), elevated glucose levels were observed after
OCT (6.2 0.3 mmol/liter; P 0.05), 250 g SOM230 (6.1
0.8 mmol/liter; P  0.05) and 100 g SOM230 (5.8  0.6
mmol/liter; P  0.05) administration (Fig. 4A). When no
study drug was administered, lunch induced a physiological
increase in mean glucose levels to a maximum of 6.1  0.3
mmol/liter. Similar postprandial responses were observed
on all three treatment days (OCT, 6.8  0.5 mmol/liter; 250
g SOM230, 7.1 0.6 mmol/liter; and 100 g SOM230, 6.8
0.4 mmol/liter). The highest plasma glucose levels were 10.8
and 13.1 mmol/liter 5 h after injection of OCT and 250 g
SOM230, respectively, and were both observed in patient 1,
who was known to have an impaired glucose tolerance (as-
sessed by oGTT before start of the trial). Overall, there was
a trend that OCT and both SOM230 dosages induced a com-
parable increase in mean glucose levels, that responded
equally to a meal at 1230 h, compared with CD.
OCT induced an inhibitory effect on mean plasma insulin
levels compared with CD, which sustained until 2 h after
lunch (1200–1430 h; P  0.05). Mean insulin levels seemed
not to be affected by both SOM230 dosages because also after
lunch a similar increase in insulin levels was observed as on
CD (Fig. 4B). Patient 12 had severe insulin resistance. On the
CD, 30 min after lunch was consumed, a sharp increase in
plasma insulin levels to a maximum 348 mU/liter was found.
This was even more pronounced after 250 g SOM230 was
administered, when insulin levels rose to a maximum of 903
mU/liter (1 h after lunch). However, the blood glucose con-
centrations of this patient remained within the range of the
other nondiabetic patients (Fig. 4A).
In vitro studies
Apart from the direct effects of OCT and SOM230 on GH
release by cultured pituitary tumor cells from two patients,
the native peptide SS was also tested. GH production in the
control wells from the adenoma cells of patients 6 and 12 after
a 72-h incubation amounted to 228  40 and 312  18 ng/
dish, respectively. In agreement with the in vivo response of
patients 6 and 12 (Fig. 2, A and B, respectively), 10 nm
SOM230 lowered significantly GH secretion by 32.7  6.8
and23 6.9% in the primary tumor cell cultures of patients
6 and 12, respectively (P  0.05 in both instances), whereas
10 nm OCT inhibited only the GH secretion in the adenoma
cells of patient 6 (26.1  10.5%; P  0.05; Fig. 5A). SS
lowered GH secretion in both primary cultures as well
FIG. 4. Mean (SEM) serum glucose (A) and insulin (B) profiles of 11
patients (one patient was excluded because of insulin-treated type 2
diabetes) during CD (f—f) and on treatment days after sc injection
of 100 g OCT (*—*), 250 g SOM230 (Œ—Œ), and 100 g SOM230
(E—E).
FIG. 5. In vitro data of two patients. Percentual inhibition of GH
secretion by 10 nM OCT, SOM230, and SS compared with control,
after a 72-h incubation in primary cultured pituitary adenoma cells
from patients 6 () and 12 (f). Data are expressed as mean  SEM;
*, P 0.05 treatment vs. control (A). Quantitative analysis of RT-PCR
showing the different amount of sst2 and sst5 mRNAs in the adenoma
tissues of patients 6 (pat.6) and 12 (pat.12), calculated relative to the
amount of HPRT and given in arbitrary units (B).
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(32.4  8.5 and 30.1  1.8%, respectively; P  0.05, Fig.
5A). Furthermore, evaluation of the relative mRNA expres-
sion levels for sst2 and sst5 in both cases revealed an inter-
esting difference. The adenoma cells from patient 6, who
responded to all three compounds, had a relatively high
expression of sst2 (193 copies/HPRT) and a relatively low
expression of sst5 (577 copies/HPRT). Compared with
mRNA expression levels in the adenoma cells of patient 12,
which were responsive only to SOM230 and SS treatment, an
opposite mRNA expression pattern was found (Fig. 5B). The
pituitary adenoma of patient 12 contained relatively high
mRNA expression levels for sst5 (793 copies/HPRT) and
approximately 5-fold lower sst2 mRNA expression levels
than those of patient 6 (37 copies/HPRT). The adenoma was
in vivo and in vitro not responsive to OCT but demonstrated
significant sensitivity to both dosages of SOM230 in vivo and
to SOM230 in vitro. This suggests the involvement of sst5
subtype in the GH-release inhibitory effect in this particular
case.
Discussion
In the present study, the recently developed SS analog
SOM230, exhibiting a universal binding profile that was
demonstrated to effectively suppress GH levels in normal
monkeys and rodents (16), was administered for the first time
in acromegalic patients to assess its efficacy in comparison
with OCT. The acute effects of a single dose of 250 g
SOM230 and 100 g OCT on circulating GH concentrations
demonstrated three patterns of response in the 12 patients
investigated. In eight patients, both SS analogs were equally
effective in lowering GH levels. This suggests that in these
patients the sst2 subtype is the major receptor on the pituitary
adenoma, which is responsible for mediating these inhibitory
effects. It is well known that sst2 especially is involved in the
inhibitory actions of SS and SS analogs on hormone secretion,
both in primary cultured human fetal pituitary cells and
GH-secreting pituitary adenoma cells as well (12, 20). The
relative amount of mRNA expression levels of this receptor
subtype was positively correlated with the sensitivity to OCT
treatment in vitro (21). The in vitro data of patient 6 illustrate
in this group of equal responders that the relatively high
mRNA level for sst2 combined with the good affinity of both
SOM230 and OCT account for the suppressive effects of both
drugs on GH secretion in this group of patients. SOM230 has
a 2.5 times lower affinity to sst2 than OCT, which explains the
similar effect of 250 g SOM230 and 100 g OCT in this
category of acromegalic patients.
The second pattern of response, illustrated by patient 12 in
which SOM230 is far more efficacious, compared with OCT
in suppressing GH levels, was observed in three patients. A
pivotal role for sst5 in mediating suppression of GH release
is probable. The in vitro data of patient 12 show relatively low
mRNA expression levels for sst2 and higher expression levels
for sst5. The IC50 for sst5 of SOM230 is 0.16 nmol/liter, and
that of OCT is 40 times higher (6.3 nmol/liter), pointing to
the higher affinity of SOM230 for the sst5 subtype. These
observations, together with the the in vitro significant inhi-
bition by the native SS on the primary culture of adenoma
cells, suggest that both SS and SOM230 exert their potent
effects in this particular tumor via sst5 subtype. So far, the
role of sst5 in mediating GH release was investigated only in
studies with primary cultures of pituitary adenoma cells
obtained from acromegalic patients (20, 21). Saveanu et al.
(15) found a 30-fold higher expression of sst5 mRNA, com-
pared with sst2 mRNA, in four adenomas poorly responsive
to OCT. The addition of the sst5-specific analog BIM23268 to
the medium achieved a maximal GH suppression. This sug-
gests a rescue through sst5 when tumors are only partially
sensitive to OCT (15). SOM230 induced a 3-fold stronger
inhibition than OCT on GH release by cultured rat pituitary
cells and a pronounced inhibition of plasma IGF-I levels in
rodents after 18 wk of treatment, which again is suggestive
for sst5 involvement (16).
We present the first clinical evidence that the sst5 subtype
may indeed play an essential role in mediating the in vivo
suppressive actions by SOM230 on GH concentrations in
three acromegalic patients, which were (partially) unrespon-
sive to OCT. Because SOM230 is able to lower GH levels in
both subgroups of patients, coupled with sst2 and sst5 sub-
type physiology, respectively, this novel SS analog has a clear
advantage over OCT and might increase the number of pa-
tients who can be biochemically controlled during long-term
medical treatment. Furthermore, in patient 12, 100 and 250
g SOM230 suppressed GH levels equally. In this particular
case, increasing the SOM230 dosage by a factor 2.5 did not
result in a further increase in GH inhibition. This phenom-
enon is already known for patients who are sensitive to OCT
treatment: a similar GH suppression is found on sc injections
with OCT dosages in the range of 100-1500g/d (22, 23). This
could indicate that the density of the predominantly ex-
pressed sst determines the response to a SS analog: in GH-
secreting adenomas expressing sst2 in high density, OCT is
able to suppress GH levels significantly. However, if sst2 is
almost not expressed on the pituitary adenoma, sst5 mediates
the GH-suppressive effects of SS and SS analogs. The dose-
response curves of OCT and SOM230 seem to reach the
plateau at low levels when high densities of sst2 and sst5,
respectively, are expressed. In vivo and in vitro data from this
trial emphasize that the inhibitory effects on GH release by
SS and its analogs are primarily mediated via sst2, as seen in
the group of eight equal responders to OCT and SOM230.
However, when sst2 over sst5 mRNA levels are being ex-
pressed below a certain threshold, as in patient 12, a sup-
pressive action on GH concentrations via sst5 receptors be-
comes visible. In addition, heterodimeric effects of different
sst subtypes are suggested to play a role in receptor physi-
ology (24, 25), and, as discussed previously, the BIM23244
bispecific sst25 analog has already shown to be more active
than the combination of a sst2-specific analog combined with
a sst5 specific analog on GH release (15, 26), indicating that
a heterodimeric effect by SOM230 on sst2 and sst5 subtypes
cannot be ruled out.
The third response was observed in one patient, who only
transiently responded to SOM230, whereas OCT was far
more efficacious in lowering GH levels. The most likely ex-
planation is the presence of a relatively high sst2 and a low
sst5 mRNA expression level, resulting in a high sensitivity for
OCT. Whether higher dosages of SOM230 would indeed
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induce similar lowering actions on GH concentrations as
seen by OCT, remains uncertain.
Because SS and its analogs inhibit the secretion of insulin,
impaired postprandial glucose tolerance was observed after
the acute administration of OCT (27). Similar elevations of
glucose concentrations were observed after SOM230. How-
ever, the elevated glucose levels seem not be caused by an
inhibitory action on insulin release because after SOM230
administration at 0900 h, an almost identical insulin response
was observed after lunch as on the CD. At present, the
mechanism of this transient increase in glucose levels re-
mains uncertain. Several studies support a role for sst5 to
control insulin secretion in rats, mice, and humans, whereas
sst2 mediates glucagon secretion from the pancreatic -cells
(28–31). On the basis of the SOM230 and OCT affinity pro-
files for sst2 and sst5, it seems unlikely that OCT, binding
40-fold less to sst5 compared with SOM230, would exert such
a strong and long-lasting insulin inhibition via sst5 subtype,
whereas SOM230 treatment resulted in barely any inhibition.
Therefore, these opposed effects of OCT and SOM230 on
insulin levels suggest a pivotal role for sst2 subtype in reg-
ulating human insulin secretion. In cynomolgus monkeys,
insulin, glucagon, and glucose levels remained unchanged
during 7 d of high-dose infusion with SOM230. Furthermore,
during an 18-wk treatment with pharmacological doses of
SOM230, plasma glucose levels were not changed, indicating
that SOM230 is well tolerated in rats and monkeys with
regard to glucose homeostasis (16, 32).
The promising pharmokinetic properties of SOM230
found in vivo in rats, accounting for a terminal elimination
half-life of 27 h compared with 2 h for OCT (16), did not result
in a longer duration of action of SOM230 than that of OCT.
Probably, serum SOM230 concentrations drop sooner below
a certain therapeutical level, leading to a duration of action
on GH levels comparable with that of OCT treatment.
In conclusion, our data suggest that SOM230 has the po-
tency to increase the number of acromegalic patients who can
be biochemically controlled during long-term medical treat-
ment because of its additional suppressive effects on GH
secretion via sst5. However, the subtype sst2 seems to be the
dominant receptor in controlling hypersecretion in acromeg-
aly. No serious side effects occurred during SOM230 treat-
ment. The subtle increase in glucose levels after SOM230
injection needs additional attention and cannot be explained
by sst5- or sst2-mediated action on insulin secretion. Future
studies will also address the question of whether SOM230
can control pituitary adenoma size in acromegaly better than
OCT (9). Besides sst2 and sst5, sst1 and sst3 also seem to be
involved in cell proliferation and the induction of apoptosis
(33–36). This suggests that the universal SS analog SOM230,
with good affinity for both sst1 and sst3, might have possible
antiproliferative and tumor size reducing effects as well.
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